Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 assay

Internal Medicine

Volumn 50, Issue 7, 2011, Pages 695-698

  Maruyama, Hajime ^a   Takeda, Hidetaka ^a   Dembo, Tomohisa ^a   Nagoya, Harumitsu ^a   Kato, Yuji ^a   Fukuoka, Takuya ^a   Deguchi, Ichiro ^a   Horiuchi, Yohsuke ^a   Tanahashi, Norio ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cilostazol; Clopidogrel resistance; Ischemic stroke; Platelet aggregation

Indexed keywords

CILOSTAZOL; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

AGED; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CAROTID ARTERY STENTING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT CARE; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION;

AGED; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CAROTID ARTERY DISEASES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECURRENCE; RETROSPECTIVE STUDIES; STENTS; STROKE; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79953755595     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4623     Document Type: Article

References (19)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115: 101-108, 2005.
2. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is a associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109: 3171-3175, 2004.
3. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet therapy activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 93: 456-458, 2004.
4. Müller I, Besta F, Schultz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Res 89: 783-787, 2003.
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54: 2430-2435, 2005.
6. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252: 233-238, 2002.
7. Fukuoka T, Furuya D, Takeda H, et al. Evaluation of clopidogrel resistance in ischemic stroke patients. Intern Med 50: 31-35, 2011.
8. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959-968, 2010.
9. Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 134: 351-355, 2009.
10. Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 71: 1867-1872, 2007.
11. Godino C, Mendolicchio L, Figini F, et al. Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J 7: 4, 2009.
12. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the verify thrombosis risk assessment (VERITAS) study. Thromb Res 119: 277-284, 2007.
13. Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. Am J Neuroradiol 29: 1389-1394, 2008.
14. Umemura K. The genotype difference of CYP2C19 affects pharmacokinetics of and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects. Jpn J Clin Pharmacol Ther 39: 238-242, 2008.
15. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363: 1704-1714, 2010.
16. Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 104: 46-51, 2009.
17. Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: result of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 3: 17-26, 2010.
18. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: result of the ACCEL-RESISTANCE (adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study. J Am Coll Cardiol 53: 1101-1109, 2009.
19. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 29: 2202-2211, 2008.